Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 7/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.36 |
| ▸ | HTR2C | P28335 | 2/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.36 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 3/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.34 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13628669 | 0.88 | CYP2D6 (0.39) | HTR7CYP2D6ADRA1DHTR2CADRA1A | |
| SCHEMBL13628672 | 0.83 | CYP2D6 (0.55) | CYP2D6 | |
| SCHEMBL13628673 | 0.76 | ASIC3 (0.32) | NR3C2HRH4 | |
| SCHEMBL13628525 | 0.70 | CYP2D6 (0.57) | CYP2D6 | |
| SCHEMBL7459147 | 0.67 | NOS2 (0.66) | CYP2D6NOS2AAK1 | |
| SCHEMBL13628670 | 0.66 | CYP1A2 (0.46) | — | |
| SCHEMBL15102638 | 0.66 | MAPK14 (0.42) | HRH4MAPK14 | |
| SCHEMBL2642666 | 0.66 | KCNH2 (0.41) | NOS2HRH4MAPK14 | |
| SCHEMBL14224121 | 0.65 | MTNR1A (0.51) | — | |
| SCHEMBL291728 | 0.63 | CYP2D6 (0.60) | CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612197-B2 | Reacting a nucleophil with OH group with an electrophil to form an adduct, reacting adduct with a reagent selected from oxidizing, sulfurizing or selenizing agents to produce hydroxy protected oligonucleotide, heating to deprotect hydroxy protecting group such as 2-(2-pyridyl)aminoethoxycarbonyl | The United States of America as repesented by the Secretary of the Department of Health and Human Services (US) | 2009-11-03 | — | — | US | disclosed |